Osmotica Pharmaceuticals PLC - ESG Rating & Company Profile powered by AI
If you are employed by Osmotica Pharmaceuticals PLC and you would like to licence your Sustainability rating, please contact us. Complete ESG assessment of Osmotica Pharmaceuticals PLC are reached by logging in. This Sustainability rating for Osmotica Pharmaceuticals PLC represents the company's reporting of the United Nations Sustainable Development Goals.
Osmotica Pharmaceuticals PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Osmotica Pharmaceuticals PLC | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Osmotica Pharmaceuticals PLC have an accelerator or VC vehicle to help deliver innovation?
Does Osmotica Pharmaceuticals PLC disclose current and historical energy intensity?
Does Osmotica Pharmaceuticals PLC report the average age of the workforce?
Does Osmotica Pharmaceuticals PLC reference operational or capital allocation in relation to climate change?
Does Osmotica Pharmaceuticals PLC disclose its ethnicity pay gap?
Does Osmotica Pharmaceuticals PLC disclose cybersecurity risks?
Does Osmotica Pharmaceuticals PLC offer flexible work?
Does Osmotica Pharmaceuticals PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Osmotica Pharmaceuticals PLC disclose the number of employees in R&D functions?
Does Osmotica Pharmaceuticals PLC conduct supply chain audits?
Does Osmotica Pharmaceuticals PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Osmotica Pharmaceuticals PLC conduct 360 degree staff reviews?
Does Osmotica Pharmaceuticals PLC disclose the individual responsible for D&I?
Does Osmotica Pharmaceuticals PLC disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Osmotica Pharmaceuticals PLC disclose current and / or historical scope 2 emissions?
Does Osmotica Pharmaceuticals PLC disclose water use targets?
Does Osmotica Pharmaceuticals PLC have careers partnerships with academic institutions?
Did Osmotica Pharmaceuticals PLC have a product recall in the last two years?
Does Osmotica Pharmaceuticals PLC disclose incidents of discrimination?
Does Osmotica Pharmaceuticals PLC allow for Work Councils/Collective Agreements to be formed?
Has Osmotica Pharmaceuticals PLC issued a profit warning in the past 24 months?
Does Osmotica Pharmaceuticals PLC disclose parental leave metrics?
Does Osmotica Pharmaceuticals PLC disclose climate scenario or pathway analysis?
Does Osmotica Pharmaceuticals PLC disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Osmotica Pharmaceuticals PLC disclose the pay ratio of women to men?
Does Osmotica Pharmaceuticals PLC support suppliers with sustainability related research and development?
Does Osmotica Pharmaceuticals PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Osmotica Pharmaceuticals PLC reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Osmotica Pharmaceuticals PLC involved in embryonic stem cell research?
Does Osmotica Pharmaceuticals PLC disclose GHG and Air Emissions intensity?
Does Osmotica Pharmaceuticals PLC disclose its waste policy?
Does Osmotica Pharmaceuticals PLC report according to TCFD requirements?
Does Osmotica Pharmaceuticals PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Osmotica Pharmaceuticals PLC disclose energy use targets?
Does Osmotica Pharmaceuticals PLC disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Osmotica Pharmaceuticals PLC have a policy relating to cyber security?
Have a different question?
Potential Risks for Osmotica Pharmaceuticals PLC
These potential risks are based on the size, segment and geographies of the company.
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.